HOME
SEARCH
RSS FEED
SUBSCRIBE
Search Results - o
1424
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Acyl
o
xyacyl Hydrolase (AOAH) and Methods of Use
Summary: The Nati
o
nal Cancer Institute (NCI) seeks research co-development partners and/or licensees for the development of AOAH as a cancer immunotherapy. Description of Technology: Immune CheckPoint Inhibitors (ICIs) and T-cell based therapies are part of the emerging immunology-based therapies being used to treat cancers. However, the efficacy...
Published: 9/30/2025
|
Inventor(s):
Peng Jiang
,
Lanqi G
o
ng
Keywords(s):
Category(s):
C
o
llaboration Sought > Collaboration
,
C
o
llaboration Sought > Licensing
,
Applicati
o
n > Therapeutics
,
TherapeuticArea >
O
ncology
,
TherapeuticArea > Immun
o
logy
Ph
o
toactivatable Dye Compounds For Conjugate Formation And Methods of Making And Using the Same
Summary: The Nati
o
nal Cancer Institute (NCI) seeks research co-development partners and/or licensees for a new series of photo-absorbing silicon-phthalocyanine derivatives (IR702HKT) for use in near-infrared photoimmunotherapy (NIR-PIT) in the treatment of cancer. Description of Technology: Near-infrared photoimmunotherapy (NIR-PIT) is a method of...
Published: 9/30/2025
|
Inventor(s):
Peter Ch
o
yke
,
Hisataka K
o
bayashi
,
Hide
o
Takakura
,
Daiki Hara
Keywords(s):
Category(s):
Applicati
o
n > Therapeutics
,
TherapeuticArea >
O
ncology
,
C
o
llaboration Sought > Licensing
Humanized M
o
noclonal Antibodies Specific Against Human Soluble Tissue Factor (hsTF) as Diagnosis, Prevention and Therapeutic Agents for Thrombosis
Summary: The Nati
o
nal Cancer Institute (NCI) seeks research co-development partners and/or licensees for a novel humanized monoclonal antibody (58B3) that selectively targets a newly identified soluble Tissue Factor (sTF) to diagnose, prevent and treat pathological thrombosis associated with inflammation, viral/bacterial infection, sepsis and cancer...
Published: 9/29/2025
|
Inventor(s):
Zheng-gang Liu
,
Swati Ch
o
ksi
,
PeiXing Wan
Keywords(s):
Category(s):
C
o
llaboration Sought > Collaboration
,
C
o
llaboration Sought > Licensing
,
TherapeuticArea > Immun
o
logy
,
TherapeuticArea > Infecti
o
us Disease
,
TherapeuticArea >
O
ncology
,
Applicati
o
n > Diagnostics
,
Applicati
o
n > Therapeutics
C
o
mbination PDL1 and TGF Beta Blockade in Patients with HPV-Associated Malignancies
Summary: The Nati
o
nal Cancer Institute (NCI) seeks collaborations and licensees for a method to block PD-L1 and TGF-beta for the treatment of HPV-associated malignancies. Description of Technology: Advanced or relapsed human papillomavirus (HPV)-associated cancers are incurable and many of these diseases do not have a standard second line therapy....
Published: 9/29/2025
|
Inventor(s):
Julius Strauss
,
James Gulley
,
Christian Hinrichs
Keywords(s):
Category(s):
C
o
llaboration Sought > Licensing
,
Applicati
o
n > Therapeutics
,
TherapeuticArea > Immun
o
logy
,
TherapeuticArea >
O
ncology
Identificati
o
n and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein
Summary: The Nati
o
nal Cancer Institute (NCI) seeks co-development partners and licensees for a human cytotoxic T lymphocyte agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), in a cancer vaccine or T-cell targeted therapy to target many tumor types. Description of Technology: Many...
Published: 9/29/2025
|
Inventor(s):
Jeffrey Schl
o
m
,
Kw
o
ng-Yok Tsang
Keywords(s):
Category(s):
C
o
llaboration Sought > Collaboration
,
C
o
llaboration Sought > Licensing
,
Applicati
o
n > Therapeutics
,
TherapeuticArea > Immun
o
logy
,
TherapeuticArea >
O
ncology
N
o
vel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1
Summary: The Nati
o
nal Cancer Institute (NCI) seeks research co-development partners and/or licensees for the clinical translation of novel peptide-based therapeutic cancer vaccines derived from ERVMER34-1, a human endogenous retrovirus (HERV) antigen, offering a unique opportunity to address a significant unmet need in the treatment of various carcinomas. Description...
Published: 9/29/2025
|
Inventor(s):
Jeffrey Schl
o
m
,
Duane Hamilt
o
n
,
Claudia Palena
,
Renee D
o
nahue
Keywords(s):
Category(s):
TherapeuticArea > Immun
o
logy
,
TherapeuticArea >
O
ncology
,
C
o
llaboration Sought > Collaboration
,
C
o
llaboration Sought > Licensing
,
Applicati
o
n > Vaccines
Generating C
o
nditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2
Summary: The Eunice Kennedy Shriver Nati
o
nal Institute of Child Health and Human Development (NICHD) is seeking potential licensees interested in further developing or utilizing these Casq2 mouse strains. As a research tool, patent protection is not being pursued for this technology. More information to access these strains can be found here: https://www.jax.org/strain/036291...
Published: 9/29/2025
|
Inventor(s):
Karl Pfeifer
,
Bj
o
rn Knollmann
Keywords(s):
Category(s):
TherapeuticArea > Rare/Neglected Diseases
,
Applicati
o
n > Research Materials
,
C
o
llaboration Sought > Licensing
Inn
o
vative Antibody Conjugation Technology for Therapeutic and Diagnostic Applications
This pi
o
neering technology introduces a novel method for conjugating antibodies, designed to dramatically enhance their therapeutic and diagnostic performance. By improving both binding efficiency and target specificity, this approach overcomes critical limitations of existing antibody-based therapies and imaging tools. The result is a versatile platform...
Published: 9/22/2025
|
Inventor(s):
Frank B
o
rris
,
Parinaz Fathi
,
Kaitlyn Sadtler
Keywords(s):
Category(s):
Applicati
o
n
,
Applicati
o
n > Therapeutics
,
Applicati
o
n > Diagnostics
,
TherapeuticArea >
O
ncology
,
TherapeuticArea > Infecti
o
us Disease
Advanced Bi
o
degradable Polymers for Medical Devices
This breakthr
o
ugh technology features advanced biodegradable polymers engineered specifically for medical device applications. Designed to safely degrade within the body, these polymers eliminate the need for surgical removal, significantly reducing the risk of long-term complications and enhancing overall patient safety. The polymers’ controlled...
Published: 9/22/2025
|
Inventor(s):
Ravi L
o
kwani
,
Kaitlyn Sadtler
Keywords(s):
Category(s):
Applicati
o
n > Medical Devices
,
Applicati
o
n > Therapeutics
,
ResearchPr
o
ducts > Human Cell Lines
Rapid Spectral Unmixing Using Spectrally Interp
o
lated Background Reduction (SIBR) for Fluorescence Imaging
This breakthr
o
ugh technology introduces Spectrally Interpolated Background Reduction (SIBR), a novel process that enables the rapid and efficient calculation of fluorescence signals from individual probes in complex, multi-labeled samples. Unlike traditional methods that require extensive computational power, SIBR provides real-time unmixing of signals...
Published: 9/22/2025
|
Inventor(s):
Harshad Vishwasra
o
Keywords(s):
Category(s):
Applicati
o
n > Medical Devices
,
Applicati
o
n > Research Materials
,
Applicati
o
n > Diagnostics
1
2
3
4
5
6
7
8
9
10
...
Home
|
Search
|
RSS
|
Subscribe
© 2025. All Rights Reserved. Powered by
Inteum